# Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)

> **NCT01757197** · PHASE2 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 2 (actual)

## Conditions studied

- Glucocorticosteroid Refractory Acute GVHD

## Interventions

- **DRUG:** Toclizumab

## Key facts

- **NCT ID:** NCT01757197
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11-07
- **Primary completion:** 2014-06-17
- **Final completion:** 2014-06-17
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2018-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01757197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01757197, "Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01757197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*